The FDA’s effort to curb high drug costs by accelerating approvals of cheaper medicines similar to expensive biologics will ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

On July 29, 2025, during a joint press conference, the U.S. Food and Drug Administration (FDA or the Agency) recommended to the Drug Enforcement Administration (DEA) to classify 7-hydroxymitragynine ...

The FDA today announced a plan to publicly release complete response letters at the same time they are issued to sponsoring companies, part of what the agency calls a push toward “radical transparency ...

ViTAA Medical Secures FDA 510(k) Clearance for AiORTA™ Plan — Marking the First Step in Its Hyper-Precise Aortic Care Platform FDA clearance marks a pivotal milestone in ViTAA’s broader AiORTA™ suite, ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

News Nation/World FDA’s plan to boost biosimilar drugs could stall at the patent office Nov. 28, 2025 Updated Sat., Nov. 29, 2025 at 9:37 p.m. Food and Drug Administration (FDA) Commissioner Dr. Marty ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

These officials were thrilled Oct. 29 when FDA Commissioner Marty Makary announced the agency's plan, which he said would halve the time and money needed to get what are called "biosimilar" drugs to ...